Sandoz Pays $265 Million For Settlement In The US


(MENAFN- Swissinfo) The generics specialist Sandoz is resolving a long-standing antitrust litigation. Formerly a division of Novartis from which it spun off last October, Sandoz has reached a settlement with the plaintiff group in a lawsuit that has been ongoing for years.

This content was published on February 29, 2024 - 09:11 2 minutes Keystone-SDA

Sandoz will pay the group of direct sellers $265 million (CHF301 million), the Basel-based company announced on Thursday. In return, the plaintiff group, which consists of US direct sellers such as CVS and Walgreens, will drop all claims. This is now subject to the approval of the court.

The settlement is one of the last from a years-long investigation by the US Department of Justice into generics manufacturers on suspicion of illegal price fixing. An agreement had already been reached with the US Department of Justice in 2020, in which Sandoz paid almost $200 million. At the time of the agreement in 2020, Sandoz was still part of Novartis.

More More Novartis plans to offload Sandoz in fourth quarter of 2023

This content was published on Jul 18, 2023 The pharmaceutical firm plans to buy back as much as $15 billion (CHF12.88 billion) in shares as it prepares to spin off its Sandoz generics unit.

Read more: Novartis plans to offload Sandoz in fourth quarter of 2023

With the agreement now reached, which does not contain any admission of wrongdoing by Sandoz US, all claims for damages by the group of direct purchasers will be settled, Sandoz further announced. The agreement also includes a release of claims relating to alleged conduct between 2009 and 2019 and to all drugs that are the subject of the direct purchaser class actions.

The $265 million will reportedly be recognised in the company's financial results for 2023.

Translated from German by DeepL/amva

This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here .

If you want to know more about how we work, have a look here , and if you have feedback on this news story please write to ... .

Articles in this story
  • Novartis plans to offload Sandoz in fourth quarter of 2023

In compliance with the JTI standards

More: SWI swissinfo certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here . Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at ... .

MENAFN03032024000210011054ID1107927072


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.